Most Viewed Infliximab Current Events | Infliximab News
|
|
|
Sort By:
Relevance | Date |
New Treatment Promising For Ulcerative Colitis Sufferers
For people with the chronic disease ulcerative colitis, life can be limited to few social functions and trips away from home. view more (2006-01-04)
Drug breakthrough for psoriasis sufferers
An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms. view more (2005-10-14)
Stubborn ulcerative colitis responds to arthritis drug, review finds
In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other treatments don't work. view more (2006-09-12)
Rheumatoid arthritis drug linked to serious infections and cancers
A new meta-analysis of many previous studies of TNF- (tumor necrosis factor) blocking antibodies for treatment of rheumatoid arthritis has confirmed a previously discovered increased risk for serious infection and has found that cancer also is a potential risk associated with the drugs. view more (2006-05-17)
Where do new therapies work best?
An observational study to investigate how new therapies for rheumatic diseases perform across different conditions has revealed that they may be more successful in certain conditions. view more (2006-06-23)
New therapeutic targets in the treatment of ulcerative colitis
Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years. view more (2007-11-14)
Remicade therapy shown to improve productivity in patients treated for chronic plaque psoriasis
Investigators reported today at the American Academy of Dermatology annual meeting that patients with moderate to severe plaque psoriasis receiving REMICADE® (infliximab) induction and maintenance therapy experienced significant improvements in productivity at week 10, which were sustained through week 50. view more (2007-02-05)
Monoclonal antibody reduces exacerbations in asthmatics
Patients with symptomatic moderate asthma who were treated with anti-tumor necrosis factor alpha, an anti-inflammatory monoclonal antibody, experienced significantly fewer disease exacerbations than individuals taking a placebo. view more (2006-10-02)
New analyses reinforce efficacy of Remicade in treatment of severe psoriasis
Findings from an integrated analysis of data from three pivotal, randomized, placebo-controlled trials showed that at week 10 more than three-quarters of patients with severe psoriasis receiving REMICADE® (infliximab) 3 mg/kg or 5 mg/kg achieved a 75 percent improvement in the chronic, inflammatory skin disease as measured by the Psoriasis... view more... (2007-02-05)
New Guidelines for Treating Rheumatoid Arthritis
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB). view more (2008-07-23)
The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
Patients with IBD have high risk of infection by hepatitis viruses B or C because during the course of their disease, they need blood transfusions, and sometimes surgical and endoscopic procedures for diagnosis and treatment. view more (2008-09-18)
TNF-Alpha Blocker Infliximab Highly Effective For Patients With Ankylosing Spondylitis
BERLIN, Germany - 6 April 2002 -- For the first time, there is a therapy that can significantly reduce disease activity for the majority of patients with ankylosing spondylitis (AS), a chronic inflammatory rheumatic disease that often leads to stiffening and subsequent fusion of the spine. The study, published in the April 6 issue of "The... view more... (2002-04-05)
Promising drug fails to improve COPD symptoms
A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial. view more (2007-05-01)
Top anti-arthritis drugs cause skin disease (embargo changed)
Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published today in the journal Arthritis Research and Therapy. view more (2005-03-31)
Infliximab scheduled treatment has proven to be an effective strategy in IBD patients
Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients. view more (2007-10-25)
Infliximab Could Prevent Sight Loss From Behcet's Disease (p 295)
A drug used to treat rheumatoid arthritis and Crohn's disease could play an important role in preventing sight loss associated with the inflammatory disorder Behcet's disease, suggest authors of a fast-track research letter published in this week's issue of THE LANCET. Beh'§et's disease is a rare condition (although with increased incidence in... view more... (2001-07-25)
Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one... view more... (2008-06-16)
Infliximab May Offer Hope For Patients Living With Spondyloarthropathy
For the first time, there may be an effective therapeutic option for severe cases of spondyloarthropathies (SpA), a group of rheumatic inflammatory diseases that affect the spinal column, peripheral joints and tendons. The study, published in the March 6 issue of "Arthritis and Rheumatism", found that patients treated with infliximab (also known... view more... (2002-03-07)
First international guidelines for treatment of psoriatic arthritis
Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it. view more (2008-10-27)
INFLIXIMAB COULD OFFER LONG-TERM BENEFITS TO PEOPLE WITH CROHN'S DISEASE (p 1541)
Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohn's disease, conclude authors of a study in this week's issue of THE LANCET. Crohn's disease is a chronic inflammatory disorder of the intestines. Patients often have to be treated with steroids, which are associated with severe side-effects. Previous... view more... (2002-05-01)
|
|
|
|
Sort By:
Relevance | Date |
|
